Lung Cancer Frontiers ^TM

"The purpose of Lung Cancer Frontiers is to acquire and disseminate new knowledge about lung cancer and how it can be most quickly and effectively diagnosed and treated."

 

History of Lung Cancer Frontiers

Dr. Thomas L. Petty founded Lung Cancer Frontiers in 1996, when he saw a need to stimulate interest in lung cancer among healthcare providers.  Primarily written for pulmonologists, this newsletter is dedicated to advancing knowledge about lung cancer, with an emphasis on early diagnosis and treatment.  In April 2008, National Jewish Health became the new home of Lung Cancer Frontiers.

Lung Cancer Frontiers Editorial Board

Contact The Editors

---

2010 Issues

Issue 39

• In Memoriam: Thomas L. Petty, MD
• Gene Expression Profiles for the Treatment of Non-small Cell Lung Cancer: The Promise of Personalized Cancer Therapy, by John Strickler, MD and Anil Potti, MD
• Selections from the Peer-Reviewed Literature, by Patrick Nana-Sinkam, MD
  

2009 Issues

Issue 38

• Screening for Lung Cancer, by Gerard A. Silvestri, MD, MS
• Selections from the Peer-Reviewed Literature, by Richard A. Matthay, MD

Issue 37

• EGFR Testing in Lung Cancer is Ready for Prime Time, by Fred R. Hirsch, MD, PhD
• Selections from the Peer-Reviewed Literature, by York E. Miller, MD

Issue 36

• Screening for Lung Cancer, by Thomas L. Petty, MD
• Message from Michael Salem, MD, President and CEO of National Jewish Health
• Informing the Decision about Being Screened for Lung Cancer, by Claudia I. Henschke, PhD, MD, et al., for the International Early Lung Cancer Action Program Investigators

2008 Issues

Issue 35

• Interventional Bronchoscopy in Lung Cancer Diagnosis and Staging, Part 2, by Ali I. Musani, MD
• Selections from the Peer-Reviewed Literature, by Thomas L. Petty, MD

Issue 34

• Nicotine Receptors and the Risk of Lung Cancer, by Steinn Jonsson, MD, FCCP
• Interventional Bronchoscopy in Lung Cancer Diagnosis and Staging, Part 1, by Ali I. Musani, MD, FCCP

Issue 33

• New Era Begins for Lung Cancer Frontiers, by Thomas L. Petty, MD
• Message from Michael Salem, MD, President and CEO of National Jewish Medical and Research Center
• ACCP 2007 Lung Cancer Recommendations: A Commentary, by Robert Keith, MD
• Selections from the Peer-Reviewed Literature, by Thomas L. Petty, MD 

2007 Issues

Issue 32
Progress in Lung Cancer
by Richard A. Matthay, MD

Issue 31
New Genomic and Proteomic Studies in Lung Cancer Biomarker Detection
by Patrick Nana-Sinkam, MD

Issue 30
Two New Observational Studies Suggest Future Directions in Lung Cancer Chemoprevention
by York E. Miller, MD 

Issue 29
Study Supports Early Screening for Lung Cancer
by Thomas L. Petty, MD

2006 Issues

Issue 28
7th Perspectives in Lung Cancer Conference, Athens, Greece
by Paul Baas, MD

Issue 27
Higher Lung Cancer Risk in Women!
by Thomas L. Petty, MD

Issue 26
CT: A Public Health Measure in Lung Cancer Control
by James Mulshine, MD 

Issue 25
Lung Cancer Frontiers: 10 Year Anniversary
by Thomas L. Petty, MD 

2005 Issues

Issue 24
New Directions for Lung Cancer Frontiers
by Thomas L. Petty, MD

Issue 23  
Spirometry Now High Priority
by Thomas L. Petty, MD

Issue 22  
Avastin Effective in Advanced Lung Cancer
by Thomas L. Petty, MD 

Issue 21
Hopes for 2005: Diminishing the Dogma Drag
by Thomas L. Petty, MD 

2004 Issues

Issue 20  
Landmark Trials of Adjuvant Chemotherapy Following Complete Surgical Resection
by James R. Jett, MD 

Issue 19   
A US Preventive Services Chest Task Force Continues to Recommend Against Screening
by Thomas L. Petty, MD 

Issue 18
Comments on Endobronchial Diagnosis and Treatment, from the 10th IASLC Conference on Lung Cancer, Vancouver, BC
by T.G. Sutedja, MD

Lung Cancer Frontiers^TM is a registered trademark of National Jewish Health.